
NexArc Strategies (NexArc) has officially launched as a boutique research and consulting firm, offering investors analysis of antitrust and regulatory risks related to mergers, acquisitions, and corporate conduct. The firm leverages experience in both antitrust law and government regulatory processes.
According to a statement from NexArc, the firm will generate actionable assessments that can help investors navigate the complexities of antitrust regulatory scrutiny. The company’s principal, Amanda Hamilton, brings over 20 years of expertise in antitrust matters, having worked across multiple sectors in both government and private practice.
Hamilton’s career includes roles at the Federal Trade Commission (FTC), where she played a part in mergers such as Equitable/Dominion and Ardagh/Saint Gobain. Per a statement from NexArc, Hamilton also served as an Assistant Attorney General for the District of Columbia, where she collaborated with the FTC to challenge the Kroger/Albertsons merger, worked alongside the Department of Justice in litigation against Live Nation, and scrutinized RealPage’s business practices.
Beyond her government service, Hamilton has a background in legal journalism, having reported for The Capitol Forum on cases such as Standard General/Tegna, ASSA ABLOY/Spectrum Brands, and ICE/Black Knight. She also has experience in private practice, where she defended pharmaceutical companies in antitrust investigations and class actions.
Per NexArc’s statement, the firm will assist investors in understanding how regulatory decisions could impact their financial strategies. With Hamilton’s experience, NexArc is set to provide in-depth analysis on antitrust risks, helping clients anticipate potential challenges in a rapidly evolving regulatory landscape.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas